ARS Pharmaceuticals, Inc. (SPRY) stock forecast and price target
Price $3.89 · data as of November 13, 2026
12-month price target
Average target$17.00
Upside / downside+337.0%
Analysts3
ConsensusStrong buy
Low $14.00Average $17.00High $20.00
Gold marker: average target · white marker: today’s price ($3.89)
Analyst ratings
Strong buy 1Buy 3Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.87 | −7.5% | $121M |
| Next fiscal year ends December 31, 2027 | $-0.86 | +54.2% | $170M |
| Next quarter ends December 31, 2026 | $-0.28 | +34.5% | $27M |
| Quarter after ends March 31, 2027 | $-0.34 | +44.3% | $25M |
Consensus of the analysts covering ARS Pharmaceuticals, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the ARS Pharmaceuticals stock price target?
The average 12-month target from 3 analysts is $17.00, 337.0% above the current price of $3.89 Targets range from $14.00 to $20.00.
Is ARS Pharmaceuticals a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 3 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is ARS Pharmaceuticals expected to earn?
Analysts expect EPS of $-1.87 for the fiscal year ending December 31, 2026 and $-0.86 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.